Related Experiment Videos
Hydrochlorothiazide-amiloride versus hydrochlorothiazide alone for essential hypertension: effects on blood pressure
Insights
Hydrochlorothiazide-amiloride effectively lowers blood pressure, similar to hydrochlorothiazide alone. This combination drug significantly reduces the risk of hypokalemia, making it a preferred choice for hypertension management.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Hypertension is a prevalent cardiovascular risk factor.
- Hypokalemia, a common side effect of thiazide diuretics, poses significant cardiovascular risks.
- Effective blood pressure control while mitigating electrolyte imbalances is crucial in hypertension management.
Purpose of the Study:
- To compare the efficacy and safety of hydrochlorothiazide-amiloride versus hydrochlorothiazide alone in treating hypertension.
- To assess the impact of both treatments on blood pressure and serum potassium levels.
- To determine the incidence of hypokalemia in patients receiving either treatment.
Main Methods:
- A double-blind, randomized controlled trial involving 266 adults with hypertension.
- Patients were randomized to receive either hydrochlorothiazide-amiloride or hydrochlorothiazide monotherapy.
- Blood pressure and serum potassium concentrations were monitored over an 8-week treatment period.
Main Results:
- Both treatment groups showed significant reductions in blood pressure.
- Hydrochlorothiazide-amiloride resulted in a significantly lower incidence of hypokalemia (14%) compared to hydrochlorothiazide alone (29%).
- Serum potassium levels decreased in both groups, but the decline was less pronounced with the combination therapy.
Conclusions:
- Hydrochlorothiazide-amiloride and hydrochlorothiazide alone achieve comparable blood pressure reduction.
- Hydrochlorothiazide-amiloride is associated with a significantly lower risk of developing hypokalemia.
- The combination drug is a preferable option for hypertensive patients, especially those at risk of or experiencing hypokalemia.
Abstract:
In a double-blind randomized controlled trial the effects on the blood pressure and the serum potassium concentration of hydrochlorothiazide-amiloride hydrochloride (Moduret) and hydrochlorothiazide alone were compared in 266 adults who were normokalemic and had a diastolic blood pressure greater than 95 mm Hg at the time of entry into the study. The mean ages (52.2 and 53.8 years) and the proportions of men (66% and 56%) in the groups given the combination drug and hydrochlorothiazide alone respectively were similar. In the group given the combination drug the mean blood pressure, measured while the patients were supine, and the mean serum potassium level fell significantly, from 156/99 to 138/88 mm Hg and from 4.23 to 3.91 mmol/L, after 8 weeks of treatment. In the other group both measures also fell significantly, the blood pressure from 157/99 to 138/87 mm Hg and the potassium level from 4.16 to 3.69 mmol/L. The proportions of patients in the two groups with hypokalemia (14% and 29% respectively), defined as a serum potassium level below 3.5 mmol/L, differed significantly (p = 0.0026), whereas the proportions with a potassium level exceeding 4.5 mmol/L (4.5% and 3.9% respectively) were similar. Thus, the combination drug reduced the blood pressure to the same extent as hydrochlorothiazide alone but significantly less often caused hypokalemia. In light of growing concerns about the cardiovascular complications of hypokalemia, hydrochlorothiazide-amiloride appears preferable to hydrochlorothiazide alone for the treatment of some patients with hypertension.